Onxeo

Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France.

We are committed to pioneering novel, safe and effective treatments for oncology indications with an emphasis on rare and refractory tumors to improve the quality of life of patients around the world.

Our vision is to become a leader in the development of novel therapies for cancer, focusing on unmet needs, thereby creating value for patients, physicians, shareholders and stakeholders.

In 2016, Onxeo was awarded the Prix Roussel-UCLAF, one of the most prestigious awards in French biotechnology, for its revolutionary approach to cancer drug development.